9 research outputs found
On generalized Erdös spaces
No full textAbstractDuring the last years both Erdős space and complete Erdős space were topologically characterized by Dijkstra and van Mill. Applications include results about Erdős type spaces in ℓp-spaces as well as results about Polishable ideals on ω. We present an unifying theorem in terms of sets with a reflexive relation that among other things contains these apparently dissimilar results as special cases
Additional file 1 of Length of stay and cost of care associated with admissions for atrial fibrillation among patients with cancer
No full textAdditional file 1. Supplementary methods, figures and tables
WSO895709 Supplemental Material - Supplemental material for Contemporary utilization patterns and outcomes of thrombolytic administration for ischemic stroke among patients with cancer
No full textSupplemental material, WSO895709 Supplemental Material for Contemporary utilization patterns and outcomes of thrombolytic administration for ischemic stroke among patients with cancer by Jocelyn Owusu-Guha, Avirup Guha, P Elliott Miller, Sumeet Pawar, Amit K Dey, Tariq Ahmad, Hatim Attar, Farrukh T Awan, Darrion Mitchell, Nihar R Desai and Daniel Addison in International Journal of Stroke</p
Additional file 1 of Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
No full textAdditional file1: Table S1 Long-term rates, time to development, and management of new or worsened hypertension (HTN) during acalabrutinib therapy. Table S2 Distribution of maximum SBP increase from baseline, %. Table S3 Development of new or worsened hypertension among patients based on concomitant obinutuzumab treatment. Table S4 Univariable predictors for the development of new or worsened hypertension (n=280). Table S5A Multivariable predictors for the development of new or worsened hypertension, in patients not previously treated with ibrutinib (n=208). Table S5B Multivariable predictors for new hypertension alone (n=115).* Table S5C Multivariable predictors for worsened hypertension alone (n=165).*Table S6A Univariate analysis of association of single-agent baseline antihypertensive therapy (n=115) to development of worsening hypertension (HTN), excluding those on other anti-HTN medications (n=1‡). Table S6B Multivariate analysis of development of worsening hypertension (HTN), considering acalabrutinib users on single-agent baseline beta blocker therapy. Table S6C Multivariate analysis of development of worsening hypertension (HTN), considering acalabrutinib users on any single-agent baseline antihypertensive therapy. Table S6D Change in blood pressure among subjects requiring the addition of new or additional antihypertensive class within the 1st year of acalabrutinib therapy. [From the 43 patients started on a new or additional antihypertensive, 17 patients saw the addition within 12 months of acalabrutinib initiation, of which 10 were treated with the addition of a single antihypertensive drug, 9 had pre- and post-antihypertensive blood pressures; another 7 (out of 17) required initiation of ≥ 2 antihypertensives and had available blood pressure measures pre- and 12 months post-initiation of the first antihypertensive added during acalabrutinib use.] Table S7 Occurrence of major adverse cardiovascular events (MACE), by acalabrutinib-related hypertension (HTN) status. Table S8A Multivariable analysis for the development of MACE during acalabrutinib use, considering development of new or worsened HTN as a time-dependent covariate.*Table S8B Multivariable analysis for the development of AF during acalabrutinib use, considering development of new or worsened HTN as a non-time-dependent covariate. Table S9 Cumulative incidence of new, predicted, and grade 3 or more HTN over time. Figure S1 Study Cohort Diagram. From a registry of all patients with hematologic malignancies treated with acalabrutinib over a 6-year period, those with available blood pressures were included. HTN, hypertension. Figure S2. Risk of AF development, in relationship of observed peak SBP increase within 12 months of acalabrutinib initiation. AF, atrial fibrillation; SBP, systolic blood pressure. Figure S3. Cumulative incidence of disease progression or death among those remaining on acalabrutinib beyond 90 days (landmark) alone, without initial progression or death, by new or worsened hypertension status
DataSheet_1_Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias.zip
No full textT-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. There was no survival difference in patients with CTCL or T-LGLL and concomitant PCD when treated with standard therapy directed at the T-cell malignancy when compared to historical controls. However, patients with PTCL and concomitant PCD had significantly inferior outcomes with rapid progression and worse OS and PFS at 1.7 years (p=0.006) and 4.8 months (p=0.08), respectively, when compared to historical controls for patients with PTCL, although the limited number of patients included in this analysis precludes drawing definitive conclusions. Treatment directed at the T-cell malignancy resulted in the eradication of the PCD clone in multiple patients (15.4%) including one with multiple myeloma (MM) who experienced a complete response after starting therapy directed at the T-cell malignancy. For patients with T-cell malignancies and concomitant PCD, treatment with standard T-cell-directed therapies is recommended based on this analysis with continued follow-up and monitoring of the concomitant PCD. Further studies are needed to definitively elucidate the increased risk of relapse in patients with PTCL and concomitant PCD, and larger, multi-center cohorts are needed to validate these findings across T-cell malignancies and PCDs.</p
Image_1_Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias.png
No full textT-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. There was no survival difference in patients with CTCL or T-LGLL and concomitant PCD when treated with standard therapy directed at the T-cell malignancy when compared to historical controls. However, patients with PTCL and concomitant PCD had significantly inferior outcomes with rapid progression and worse OS and PFS at 1.7 years (p=0.006) and 4.8 months (p=0.08), respectively, when compared to historical controls for patients with PTCL, although the limited number of patients included in this analysis precludes drawing definitive conclusions. Treatment directed at the T-cell malignancy resulted in the eradication of the PCD clone in multiple patients (15.4%) including one with multiple myeloma (MM) who experienced a complete response after starting therapy directed at the T-cell malignancy. For patients with T-cell malignancies and concomitant PCD, treatment with standard T-cell-directed therapies is recommended based on this analysis with continued follow-up and monitoring of the concomitant PCD. Further studies are needed to definitively elucidate the increased risk of relapse in patients with PTCL and concomitant PCD, and larger, multi-center cohorts are needed to validate these findings across T-cell malignancies and PCDs.</p
Acoustic Mist Ionization Platform for Direct and Contactless Ultrahigh-Throughput Mass Spectrometry Analysis of Liquid Samples
No full textMass
spectrometry (MS) has many advantages as a quantitative detection
technology for applications within drug discovery. However, current
methods of liquid sample introduction to a detector are slow and limit
the use of mass spectrometry for kinetic and high-throughput applications.
We present the development of an acoustic mist ionization (AMI) interface
capable of contactless nanoliter-scale “infusion” of
up to three individual samples per second into the mass detector.
Installing simple plate handling automation allowed us to reach a
throughput of 100 000 samples per day on a single mass spectrometer.
We applied AMI-MS to identify inhibitors of a human histone deacetylase
from AstraZeneca’s collection of 2 million small molecules
and measured their half-maximal inhibitory concentration. The speed,
sensitivity, simplicity, robustness, and consumption of nanoliter
volumes of sample suggest that this technology will have a major impact
across many areas of basic and applied research
Acoustic Mist Ionization Platform for Direct and Contactless Ultrahigh-Throughput Mass Spectrometry Analysis of Liquid Samples
No full textMass
spectrometry (MS) has many advantages as a quantitative detection
technology for applications within drug discovery. However, current
methods of liquid sample introduction to a detector are slow and limit
the use of mass spectrometry for kinetic and high-throughput applications.
We present the development of an acoustic mist ionization (AMI) interface
capable of contactless nanoliter-scale “infusion” of
up to three individual samples per second into the mass detector.
Installing simple plate handling automation allowed us to reach a
throughput of 100 000 samples per day on a single mass spectrometer.
We applied AMI-MS to identify inhibitors of a human histone deacetylase
from AstraZeneca’s collection of 2 million small molecules
and measured their half-maximal inhibitory concentration. The speed,
sensitivity, simplicity, robustness, and consumption of nanoliter
volumes of sample suggest that this technology will have a major impact
across many areas of basic and applied research
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019
No full textThe global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 201
